A randomized controlled clinical trial. No clear benefit to prophylactic central neck dissection in patients with clinically node negative papillary thyroid cancer. Ann Surg 2020; 272: 496-503.
Published: 20th October 2020
Authors: Sippel RS, Robbins SE, Poehls JL, Pitt SC, Chen H, Leverson G et al.
Sixty patients were included. One third who had central node dissection had microscopic nodal involvement. Oncological outcomes were similar after one year.
You may also be interested in
Lateral neck sentinel lymph node biopsy in papillary thyroid carcinoma, is it really necessary? A randomized, controlled study. Surgery 2015; 157: 518-525.
Authors: Lee SK, Lee JH, Bae SY, Kim J, Kim M, Lee H-C et al. et al.
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double blind, phase 3 trial. Lancet 2014; 384: 319-328.
Authors: Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L et al. et al.
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized double-blind phase III trial. J Clin Oncol 2012; 30: 134-141.
Authors: Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M et al. et al.
Randomized prospective evaluation of frozen-section analysis for follicular neoplasms of the thyroid. Ann Surg 2001; 233: 716-22.
Authors: Udelsman R, Westra WH, Donovan PI, Sohn TA, Cameron JL.